Oasmia Pharmaceutical AB
Interim report for the period May – July 2014
DGAP-News: Oasmia Pharmaceutical AB 05.09.2014 / 08:58 --------------------------------------------------------------------- Paccal Vet(R)-CA1 introduced in the US Uppsala, Sweden, 2014-09-05 08:58 CEST (GLOBE NEWSWIRE) -- FIRST QUARTER May 1 - July 31, 2014 -- Consolidated Net sales amounted to TSEK 994 (0)[1] -- Operating income amounted to TSEK -30,351 (-16,985) -- Net income after tax amounted to TSEK -32,989 (-18,224) -- Earnings per share amounted to SEK -0.38 (-0.22) -- Comprehensive income amounted to TSEK -32,989 (-18,224) -- The Swedish Medical Products Agency extended Oasmia's production license to also include sales of human pharmaceuticals within the EU -- Paccal Vet-CA1 was introduced on the US market by Abbott Animal Health -- Paclical successfully met the endpoints in a large-scale Phase III study -- Oasmia expanded its production agreement with Baxter -- Oasmia signed research agreement for the XR-17 technology -- Oasmia completed a MSEK 50 directed share issue EVENTS AFTER THE CLOSING DAY -- The right of the Board of Directors and company management to acquire warrants during the period January 1 to August 15, 2014 has not been utilized -- Oasmia's bank loan of MSEK 40 has been extended and expires September 30, 2014 -- Anders Blom has been appointed Executive Vice President in Oasmia. He is succeeding Hans Sundin who is nominated to become a new member of the Board of Directors of Oasmia CEO COMMENTS: 'During the first quarter we reached some very important milestones for the company, and over this period, we could announce a number of exciting news, including the launch of Paccal Vet-CA1 in the US by our partner Abbott Animal Health and positive top line results from our pivotal phase III clinical study of Paclical', commented Julian Aleksov, CEO and President of Oasmia. [1]The numbers in parentheses show the results from the corresponding period of the previous year Mikael Widell, Vice President Communications Phone +46 70 311 99 60 E-mail: Mikael.Widell@oasmia.com News Source: NASDAQ OMX --------------------------------------------------------------------- 05.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden ISIN: SE0000722365 End of News DGAP News-Service --------------------------------------------------------------------- 285696 05.09.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden